About Intec Pharma

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill® (AP) platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.
Read More

Click the video above to see how Intec’s unique delivery system allows for better absorption in specific applications.

A Novel Drug Delivery System

The Accordion Pill is a drug delivery system that uses biodegradable polymeric films, which combine and load drugs and actives ingredients onto these films, folds them into an undulated shape and then places them inside a capsule. This innovative drug delivery system has a number of unique advantages based on its gastric retentive properties. With AP, drug is released slowly in the stomach over hours, allowing the body to absorb it more steadily. When the pill is done, it simply dissolves in the GI tract.

This novel drug delivery system can improve PK, allows for high drug loading and is ideally suited for compounds with:

  • Narrow Absorption Window
  • Poor solubility
  • Act locally in the stomach or in the upper GI tract

Read More

Latest Press Releases

  • Intec Pharma Issues Letter to Shareholders January 9, 2020 JERUSALEM , Jan. 9, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today provides a business and clinical update on its development programs with the Company's proprietary oral drug delivery system, the Accordion Pill ® platform, in a Letter to Shareholders. Continue Reading
  • Intec Pharma Provides Update on Novartis Feasibility and Option Agreement December 11, 2019 JERUSALEM , Dec. 11, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the termination of the Feasibility and Option agreement with Novartis for the development of a custom-designed Accordion Pill ® (AP) for a proprietary Novartis compound, despite Continue Reading

Jeffrey A. Meckler, Intec Pharma’s Vice Chairman and CEO, speaks about the Company’s development program in Parkinson’s disease on World Parkinson’s Disease Day 2018.